Sanofi Pasteur, the vaccines division of Sanofi, announces published data on a vaccine strategy that elicited a broadly-reactive response against seasonal and pandemic H1N1 influenza viruses in mice. The article, entitled “Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses,” appears in the current issue of the Journal of Virology. Sanofi Pasteur has an R&D collaboration agreement with the University of Georgia and representatives of both organizations will be presenting the data tomorrow, March 30, at the 2016 World Vaccine Congress being held in Washington, D.C.
Previously, a novel hemagglutinin (HA) for H5N1 influenza was derived using a methodology termed computationally optimized broadly reactive antigen (COBRA). This COBRA HA elicited a broad antibody response against H5N1 isolates from different clades in mice and nonhuman primates. In this new publication, the authors present pre-clinical efficacy data demonstrating that COBRA technology can be extended to elicit antibodies against many drifted H1 strains and has the potential to be used in the development of a “subtype universal” vaccine. According to the authors, “One of the challenges of developing next generation influenza A vaccines is the diversity of antigenically distinct isolates. We now report the characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1 influenza isolates.”
As described in the publication, nine HA COBRA candidates were designed and assessed as vaccines used alone, in cocktails, or in prime-boost combinations. The most effective regimens elicited the broadest hemagglutination-inhibition (HAI) response against a panel of H1N1 viruses isolated over the past 100 years – even against viruses whose sequences were not included in the design strategy. This study represents the first demonstration of a COBRA-based HA vaccine strategy that elicits a broadly-reactive response against both seasonal and pandemic H1N1 isolates.
Sanofi Pasteur has an existing R&D collaboration agreement with the University of Georgia to further design and develop novel synthetic vaccines based on the HA protein to help protect against disease caused by seasonal influenza strains spanning several years, including drifted strains not yet in existence. This would provide an advantage over traditional influenza vaccine manufacturing, which depends on the selection of candidate vaccine viruses by public health authorities following analysis of data collected through active surveillance of influenza viruses circulating each year.
“This experimental and novel vaccine is generated from the sequences of many flu viruses and is designed to help protect against many strains over several years,” explained Tim Alefantis, PhD, MBA, Sanofi Pasteur’s R&D lead on the 2nd generation vaccine program and one of the authors of the published findings. “The key advantage could be broader coverage against several seasonal flu strains.” He added, “An additional advantage of this approach is that it doesn’t rely upon annual strain selection, allowing year-round manufacturing.”
According to the publication, “Universal influenza vaccine approaches have the potential to be paradigm-shifting for the influenza vaccine field, with the goal of replacing current, standard-of-care seasonal vaccines with broadly cross-protective vaccines.” However, Sanofi Pasteur Senior Vice President for R&D, John Shiver, PhD, says, “While a truly universal vaccine is the ultimate goal, we believe that a broader-spectrum vaccine could be available first to replace the current seasonal flu vaccine given annually.”
Source: Sanofi Pasteur
Filed Under: Drug Discovery